# A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

> **NCT02219490** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 1596 (actual)

## Conditions studied

- Chronic Hepatitis C Virus (HCV) Infection Genotype 1

## Interventions

- **DRUG:** ABT-450/r/ABT-267
- **DRUG:** ABT-333
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT02219490
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-30
- **Primary completion:** 2021-05-13
- **Final completion:** 2021-05-13
- **Target enrollment:** 1596 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219490, "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02219490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*